Allarity Therapeutics, Inc. (ALLR)
| Market Cap | 4.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.42M |
| Shares Out | 4.43M |
| EPS (ttm) | -36.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 502,322 |
| Open | 1.050 |
| Previous Close | 1.050 |
| Day's Range | 1.015 - 1.060 |
| 52-Week Range | 0.900 - 288.000 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 7, 2025 |
About ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; Li... [Read more]
Financial Performance
Financial StatementsNews
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / January 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarit...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Comp...
Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Compa...
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Compa...
Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Com...
Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Boston (November 18, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatme...
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options NEW YORK...
DEADLINE TOMORROW: Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (...
The Schall Law Firm Urges Shareholders In Allarity Therapeutics, Inc. To Join A Securities Fraud Case
LOS ANGELES, CA / ACCESSWIRE / November 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (...
Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
ALLR Deadline: Rosen Law Firm Urges Allarity Therapeutics, Inc. (NASDAQ: ALLR) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers and acquirers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July...
The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.
LOS ANGELES, CA / ACCESSWIRE / November 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Allarity To Contact Him Directly To Discuss Their Options If you su...
Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Should Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
The Schall Law Firm Encourages Stockholder Participation In A Case Against Allarity Therapeutics, Inc. For Fraud
LOS ANGELES, CA / ACCESSWIRE / November 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
The Schall Law Firm Encourages Shareholder Participation In A Securities Fraud Case Against Allarity Therapeutics, Inc.
LOS ANGELES, CA / ACCESSWIRE / November 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
The Schall Law Firm Invites Stockholders To Join A Lawsuit Against Allarity Therapeutics, Inc. For Fraud
LOS ANGELES, CA / ACCESSWIRE / October 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
Allarity Therapeutics Inc Is Being Sued For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
The Schall Law Firm Encourages Shareholders To Join A Securities Fraud Case Against Allarity Therapeutics, Inc.
LOS ANGELES, CA / ACCESSWIRE / October 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. ("...
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
European Patent Office to grant a patent for DRP ® companion diagnostic for Allarity's stenoparib cancer therapy